Should you buy Infosys, Dr Reddy's Labs, Paytm, Exide, other stocks today? Here is what brokerages recommend

As Dalal Street enters the February 19 session, brokerages have a bunch of stocks on their radar. Here's what Nomura, Morgan Stanley, Macquarie, Citi, UBS and BoFA Securities make of stocks such as Infosys, Dr Reddy's Laboratories, One 97 Communications (Paytm) and Exide Industries:

Dr Reddy's Labs share price target:

Nomura has maintained a 'neutral' rating on the Dr Reddy's Laboratories stock with a target of Rs 5,802.

Paytm share price target:

Morgan Stanley has maintained an 'equal-weight' rating on the One 97 Communications (Paytm) stock with a target of Rs 555.

Citi has maintained a 'sell' call on Paytm shares with a target of Rs 550.

Aurobindo Pharma share price target:

Macquarie has maintained an 'outperform' rating on the Auribindo Pharma stock with a target of Rs 1,300

Exide share price target:

Morgan Stanley has an 'overweight' rating on the Exide Industries stock with a target of Rs 373.

PB Fintech share price target:

Citi has maintained a 'buy' call on the PB Fintech stock with a target of Rs 1,150.

Deepak Nitrate share price target:

Morgan Stanley has maintained an 'underweight' rating on the Deepak Nitrite stock with a target of Rs 1,625

Infosys share price target:

Nomura has a 'neutral' rating on the Infosys stock with a target of Rs 1,500.

MCX share price target:

UBS has maintained a 'buy' call on the MCX stock with a target of Rs 4,300.

Delhivery share price target:

BoFA Securities has maintained a 'buy' call on the Delhivery stock with a target of Rs 550.